Table 6 Immunohistochemistry results for ER, PR, HER2, cCK5/6 and EGFR
From: Female breast cancer classification using immunohistochemistry biomarkers staining in Botswana
IHC Marker | ≤50 years (n = 45, 36.0%) | >50 years (n = 80, 64.0%) | Total (n = 125, 100%) |
|---|---|---|---|
ER, n (%) | Â | Â | |
 Positive | 23 (51.1%) | 49 (61.3%) | 72 (57.6%) |
 Negative | 22 (48.9%) | 31 (38.7%) | 53 (42.4%) |
PR, n (%) | |||
 Positive | 11 (24,4%) | 30 (37.5%) | 41 (32.8%) |
 Negative | 34 (75.6%) | 50 (62.5%) | 84 (67.2%) |
HER2, n (%) | |||
 Positive | 11 (24,4%) | 15 (18.8%) | 26 (20.8%) |
 Negative | 34 (75.6%) | 65 (81.2%) | 99 (79.2%) |
Ki67, n (%) | |||
 ≤ 14% | 16 (35.6%) | 48 (60.0%) | 64 (51.2%) |
 > 14% | 29 (64.4%) | 32 (40.0%) | 61 (48.8%) |
CK5/6, n (%) | Â | Â | |
 Positive | 6 (13.3%) | 10 (12.5%) | 16 (12.8) |
 Negative | 39 (86.7%) | 70 (87.5%) | 109 (87.2%) |
EGFR, n (%) | |||
 Positive | 16 (35.6%) | 26 (32.5%) | 42 (33.6%) |
 Negative | 29 (64.4%) | 54 (67.5%) | 83 (66.4%) |
Molecular classification (n =125), n (%) | |||
 Luminal A | 8 (17.8%) | 36 (45.0%) | 44 (35.2%) |
 Luminal B | 12 (26.7%) | 11 (13.7%) | 23 (18.4%) |
 Luminal B HER2 Positive | 4 (8.8%) | 5 (6.3%) | 9 (7.2%) |
 Triple negative | 14 (31.1%) | 18 (22.5%) | 32 (25.6%) |
 HER2 enriched | 7 (15.6%) | 10 (12.5%) | 17 (13.6%) |